1
Barkley PMHNP Actual Exam Prep | 100 Latest
Questions and Correct Detailed Answers
SECTION 1: ADVANCED PSYCHOPHARMACOLOGY (Q1–30)
1. A 45-year-old man with treatment-resistant depression has failed adequate
trials of sertraline, duloxetine, and bupropion augmentation. The PMHNP is
considering adding low-dose aripiprazole. Which receptor profile best explains
aripiprazole's antidepressant augmentation efficacy at low doses?
A. Potent D2 receptor antagonism
B. Selective serotonin reuptake inhibition
C. Partial agonist activity at D2 and 5-HT1A receptors, and antagonist activity at 5-
HT2A receptors
D. Norepinephrine reuptake inhibition
: Correct Answer : C
BIGGEST EXPLANATION: Low-dose aripiprazole (2-5 mg) acts as a functional
dopamine system stabilizer. Its partial agonism at D2 receptors provides just
enough stimulation to improve anhedonia and motivation (mesolimbic pathway)
without the full agonism that could cause psychosis or the full blockade that
worsens dopamine deficiency. Simultaneously, 5-HT1A partial agonism increases
dopamine release in the prefrontal cortex, further aiding mood and cognition,
while 5-HT2A antagonism enhances serotonin and norepinephrine transmission.
At higher doses, D2 occupancy approaches levels that cause more antagonism,
but low-dose augmentation capitalizes on its unique profile to boost monoamine
circuits already partially enhanced by antidepressants. This differs from full
antagonists (A) which worsen anhedonia, SSRIs (B) which only block reuptake, and
NRIs (D) which lack serotonergic effects.
2. A 52-year-old woman on venlafaxine XR 225 mg daily develops a sudden
onset of severe headache, elevated blood pressure (190/110 mmHg),
diaphoresis, and myoclonus. She recently started sumatriptan for migraines.
Which mechanism best explains this interaction?
pg. 1
,2
A. Venlafaxine-induced norepinephrine reuptake inhibition combined with
sumatriptan's vasoconstriction causes hypertensive crisis.
B. Both drugs are metabolized by CYP2D6, leading to toxic levels.
C. Excessive serotonin agonism from combined serotonergic activity precipitating
serotonin syndrome.
D. Sumatriptan blocks alpha-1 receptors, causing unopposed beta-adrenergic
effects.
: Correct Answer : C
BIGGEST EXPLANATION: The combination of a high-dose SNRI (venlafaxine inhibits
serotonin and norepinephrine reuptake) with a triptan (sumatriptan is a 5-
HT1B/1D agonist, but also has some 5-HT1A affinity) can overstimulate serotonin
receptors, leading to serotonin syndrome. The triad of altered mental status,
autonomic instability (hypertension, tachycardia, diaphoresis), and
neuromuscular hyperactivity (myoclonus, hyperreflexia) is classic. While
venlafaxine does affect norepinephrine, the presence of myoclonus and
autonomic features without only elevated BP points to serotonin syndrome, not
just a hypertensive crisis. Triptans are not metabolized by CYP2D6 (option B is
false), and they do not block alpha-1 receptors (D). The key is recognizing that
serotonergic overload from two distinct mechanisms—reuptake inhibition plus
direct receptor agonism—can be synergistic.
3. A patient on clozapine develops myocarditis. The PMHNP must differentiate
clozapine-induced myocarditis from an acute coronary syndrome. Which
laboratory test is most specific to clozapine-induced myocarditis in this context?
A. Elevated troponin I
B. Elevated C-reactive protein (CRP)
C. Peripheral eosinophilia
D. Elevated creatine kinase-MB
: Correct Answer : C
BIGGEST EXPLANATION: Clozapine-induced myocarditis is a hypersensitivity
reaction, often occurring within the first 2 months of treatment. It is frequently
accompanied by eosinophilia, reflecting an IgE-mediated type I hypersensitivity or
a type IV hypersensitivity. While troponin (A) and CRP (B) are elevated in both
pg. 2
,3
myocarditis and ACS, eosinophilia is a hallmark that helps differentiate this drug-
induced reaction from ischemic causes. CK-MB (D) is less specific than troponin.
The presence of eosinophilia in a patient recently started on clozapine with chest
pain, dyspnea, and elevated cardiac enzymes strongly suggests clozapine-induced
myocarditis rather than a conventional myocardial infarction.
4. A 30-year-old female with bipolar I disorder, currently euthymic on lithium,
plans to become pregnant. She asks about the risk of Ebstein’s anomaly. The
PMHNP correctly states that the absolute risk of Ebstein’s anomaly with first-
trimester lithium exposure is approximately:
A. 20%
B. 10%
C. 1–2%
D. 0.05–0.1%
: Correct Answer : D
BIGGEST EXPLANATION: Early reports vastly overestimated the teratogenic risk. A
meta-analysis and large registry studies now show the absolute risk of Ebstein’s
anomaly (a tricuspid valve malformation) following first-trimester lithium
exposure is about 0.05–0.1% (1 in 1,000 to 1 in 2,000). The background
population risk is roughly 1 in 20,000. Thus, lithium increases the relative risk
about 10-20 fold, but the absolute risk remains very small. This nuanced
counseling is critical to avoid unnecessarily discontinuing a mood stabilizer that
might lead to a destabilized mother, which carries its own risks. Valproate and
carbamazepine have much higher teratogenic risks (neural tube defects 1-2% and
0.5-1%, respectively).
5. A 65-year-old man with major depressive disorder and chronic low back pain
is switched from sertraline to duloxetine. He develops mild hyponatremia (Na
128 mEq/L) and dizziness. Which mechanism most likely explains the
hyponatremia?
A. Duloxetine-induced nephrogenic diabetes insipidus
B. Syndrome of inappropriate antidiuretic hormone (SIADH) caused by increased
serotonin tone
pg. 3
, 4
C. Direct renal tubular toxicity
D. Excessive water intake due to dry mouth
: Correct Answer : B
BIGGEST EXPLANATION: SSRIs and SNRIs are well-known to cause SIADH,
particularly in older adults. Serotonin enhances ADH secretion from the posterior
pituitary, leading to water retention and dilutional hyponatremia. Duloxetine, an
SNRI, retains this serotonergic effect. The risk is higher in patients with
comorbidities, older age, and concurrent use of other drugs that affect sodium
(diuretics, carbamazepine). Symptoms such as dizziness can be due to
hyponatremia itself. Management involves discontinuing the offending agent or
reducing the dose, and fluid restriction. Nephrogenic diabetes insipidus (A) is
associated with lithium, not duloxetine.
6. A 28-year-old patient with schizophrenia on olanzapine 20 mg at bedtime
reports a 30-pound weight gain and develops new-onset type 2 diabetes. The
PMHNP decides to switch to an agent with lower metabolic risk. Which
antipsychotic carries the lowest risk of weight gain and metabolic disturbance?
A. Quetiapine
B. Risperidone
C. Ziprasidone
D. Paliperidone
: Correct Answer : C
BIGGEST EXPLANATION: Among atypical antipsychotics, ziprasidone and
lurasidone have the most favorable metabolic profiles, with minimal weight gain,
low risk of dyslipidemia, and low risk of hyperglycemia. Aripiprazole,
brexpiprazole, and cariprazine are also in the lower-risk category. Olanzapine and
clozapine carry the highest risk, followed by quetiapine and risperidone
(moderate risk). Paliperidone, a metabolite of risperidone, has a similar risk
profile with moderate weight gain and metabolic effects. Therefore, when
metabolic concerns are paramount, switching to ziprasidone is appropriate,
though it requires monitoring for QTc prolongation.
pg. 4
Barkley PMHNP Actual Exam Prep | 100 Latest
Questions and Correct Detailed Answers
SECTION 1: ADVANCED PSYCHOPHARMACOLOGY (Q1–30)
1. A 45-year-old man with treatment-resistant depression has failed adequate
trials of sertraline, duloxetine, and bupropion augmentation. The PMHNP is
considering adding low-dose aripiprazole. Which receptor profile best explains
aripiprazole's antidepressant augmentation efficacy at low doses?
A. Potent D2 receptor antagonism
B. Selective serotonin reuptake inhibition
C. Partial agonist activity at D2 and 5-HT1A receptors, and antagonist activity at 5-
HT2A receptors
D. Norepinephrine reuptake inhibition
: Correct Answer : C
BIGGEST EXPLANATION: Low-dose aripiprazole (2-5 mg) acts as a functional
dopamine system stabilizer. Its partial agonism at D2 receptors provides just
enough stimulation to improve anhedonia and motivation (mesolimbic pathway)
without the full agonism that could cause psychosis or the full blockade that
worsens dopamine deficiency. Simultaneously, 5-HT1A partial agonism increases
dopamine release in the prefrontal cortex, further aiding mood and cognition,
while 5-HT2A antagonism enhances serotonin and norepinephrine transmission.
At higher doses, D2 occupancy approaches levels that cause more antagonism,
but low-dose augmentation capitalizes on its unique profile to boost monoamine
circuits already partially enhanced by antidepressants. This differs from full
antagonists (A) which worsen anhedonia, SSRIs (B) which only block reuptake, and
NRIs (D) which lack serotonergic effects.
2. A 52-year-old woman on venlafaxine XR 225 mg daily develops a sudden
onset of severe headache, elevated blood pressure (190/110 mmHg),
diaphoresis, and myoclonus. She recently started sumatriptan for migraines.
Which mechanism best explains this interaction?
pg. 1
,2
A. Venlafaxine-induced norepinephrine reuptake inhibition combined with
sumatriptan's vasoconstriction causes hypertensive crisis.
B. Both drugs are metabolized by CYP2D6, leading to toxic levels.
C. Excessive serotonin agonism from combined serotonergic activity precipitating
serotonin syndrome.
D. Sumatriptan blocks alpha-1 receptors, causing unopposed beta-adrenergic
effects.
: Correct Answer : C
BIGGEST EXPLANATION: The combination of a high-dose SNRI (venlafaxine inhibits
serotonin and norepinephrine reuptake) with a triptan (sumatriptan is a 5-
HT1B/1D agonist, but also has some 5-HT1A affinity) can overstimulate serotonin
receptors, leading to serotonin syndrome. The triad of altered mental status,
autonomic instability (hypertension, tachycardia, diaphoresis), and
neuromuscular hyperactivity (myoclonus, hyperreflexia) is classic. While
venlafaxine does affect norepinephrine, the presence of myoclonus and
autonomic features without only elevated BP points to serotonin syndrome, not
just a hypertensive crisis. Triptans are not metabolized by CYP2D6 (option B is
false), and they do not block alpha-1 receptors (D). The key is recognizing that
serotonergic overload from two distinct mechanisms—reuptake inhibition plus
direct receptor agonism—can be synergistic.
3. A patient on clozapine develops myocarditis. The PMHNP must differentiate
clozapine-induced myocarditis from an acute coronary syndrome. Which
laboratory test is most specific to clozapine-induced myocarditis in this context?
A. Elevated troponin I
B. Elevated C-reactive protein (CRP)
C. Peripheral eosinophilia
D. Elevated creatine kinase-MB
: Correct Answer : C
BIGGEST EXPLANATION: Clozapine-induced myocarditis is a hypersensitivity
reaction, often occurring within the first 2 months of treatment. It is frequently
accompanied by eosinophilia, reflecting an IgE-mediated type I hypersensitivity or
a type IV hypersensitivity. While troponin (A) and CRP (B) are elevated in both
pg. 2
,3
myocarditis and ACS, eosinophilia is a hallmark that helps differentiate this drug-
induced reaction from ischemic causes. CK-MB (D) is less specific than troponin.
The presence of eosinophilia in a patient recently started on clozapine with chest
pain, dyspnea, and elevated cardiac enzymes strongly suggests clozapine-induced
myocarditis rather than a conventional myocardial infarction.
4. A 30-year-old female with bipolar I disorder, currently euthymic on lithium,
plans to become pregnant. She asks about the risk of Ebstein’s anomaly. The
PMHNP correctly states that the absolute risk of Ebstein’s anomaly with first-
trimester lithium exposure is approximately:
A. 20%
B. 10%
C. 1–2%
D. 0.05–0.1%
: Correct Answer : D
BIGGEST EXPLANATION: Early reports vastly overestimated the teratogenic risk. A
meta-analysis and large registry studies now show the absolute risk of Ebstein’s
anomaly (a tricuspid valve malformation) following first-trimester lithium
exposure is about 0.05–0.1% (1 in 1,000 to 1 in 2,000). The background
population risk is roughly 1 in 20,000. Thus, lithium increases the relative risk
about 10-20 fold, but the absolute risk remains very small. This nuanced
counseling is critical to avoid unnecessarily discontinuing a mood stabilizer that
might lead to a destabilized mother, which carries its own risks. Valproate and
carbamazepine have much higher teratogenic risks (neural tube defects 1-2% and
0.5-1%, respectively).
5. A 65-year-old man with major depressive disorder and chronic low back pain
is switched from sertraline to duloxetine. He develops mild hyponatremia (Na
128 mEq/L) and dizziness. Which mechanism most likely explains the
hyponatremia?
A. Duloxetine-induced nephrogenic diabetes insipidus
B. Syndrome of inappropriate antidiuretic hormone (SIADH) caused by increased
serotonin tone
pg. 3
, 4
C. Direct renal tubular toxicity
D. Excessive water intake due to dry mouth
: Correct Answer : B
BIGGEST EXPLANATION: SSRIs and SNRIs are well-known to cause SIADH,
particularly in older adults. Serotonin enhances ADH secretion from the posterior
pituitary, leading to water retention and dilutional hyponatremia. Duloxetine, an
SNRI, retains this serotonergic effect. The risk is higher in patients with
comorbidities, older age, and concurrent use of other drugs that affect sodium
(diuretics, carbamazepine). Symptoms such as dizziness can be due to
hyponatremia itself. Management involves discontinuing the offending agent or
reducing the dose, and fluid restriction. Nephrogenic diabetes insipidus (A) is
associated with lithium, not duloxetine.
6. A 28-year-old patient with schizophrenia on olanzapine 20 mg at bedtime
reports a 30-pound weight gain and develops new-onset type 2 diabetes. The
PMHNP decides to switch to an agent with lower metabolic risk. Which
antipsychotic carries the lowest risk of weight gain and metabolic disturbance?
A. Quetiapine
B. Risperidone
C. Ziprasidone
D. Paliperidone
: Correct Answer : C
BIGGEST EXPLANATION: Among atypical antipsychotics, ziprasidone and
lurasidone have the most favorable metabolic profiles, with minimal weight gain,
low risk of dyslipidemia, and low risk of hyperglycemia. Aripiprazole,
brexpiprazole, and cariprazine are also in the lower-risk category. Olanzapine and
clozapine carry the highest risk, followed by quetiapine and risperidone
(moderate risk). Paliperidone, a metabolite of risperidone, has a similar risk
profile with moderate weight gain and metabolic effects. Therefore, when
metabolic concerns are paramount, switching to ziprasidone is appropriate,
though it requires monitoring for QTc prolongation.
pg. 4
